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Mutations in the aggrecan gene () have been identified in two autosomal 
dominant skeletal dysplasias, Spondyloepiphyseal dysplasia, Kimberley type (SEDK) and 
osteochondritis dissecans, as well as in a severe recessive dysplasia, 
Spondyloepimetaphyseal dysplasia, aggrecan type. Next generation sequencing (NGS) has 
aided the identification of heterozygous mutations in individuals with short stature, 
minor skeletal defects and mild facial dysmorphisms, some of whom have advanced bone 
age (BA), poor pubertal spurt and early growth cessation as well as precocious osteoarthritis.  
	!	
Clinical and genetic characterization of 16 probands with heterozygous 	
variants, 14 with short stature and mild skeletal defects (group 1) and two with SEDK 

(group 2). Subsequently, we reviewed the literature to determine the frequency of the 
different clinical characteristics in  positive individuals. 
	
A total of 16  variants were located throughout the gene, six pathogenic 
mutations and 10 variants of unknown significance (VUS). Interestingly, brachydactyly was 
observed in all probands. Probands from group 1, with a pathogenic mutation tended to be  
shorter and 60% had an advanced BA compared to 0% in those with a VUS. A higher 
incidence of coxa valga was observed in individuals with a VUS (37% v 0%). Nevertheless, 
other features were present at similar frequencies.  

should be considered as a candidate gene in patients with short stature 	
and minor skeletal defects, particularly those with brachydactyly, and in patients with 

spondyloepiphyseal dysplasia. It is also important to note that advanced BA and 
osteoarticular complications are not obligatory conditions for aggrecanopathies/aggrecan
associated dysplasias. 
 
"	#
 skeletal dysplasia, short stature, aggrecan, ACAN, brachydactyly.
Page 4 of 29Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4 

$%&&$%
Longitudinal bone growth occurs at the growth plate as a result of chondrogenesis. It 
is regulated by a complex network of signals from endocrine and paracrine systems as well 
as interactions between cellular growth factors and extracellular matrix. Mutations in many of 	
these pathways result in growth delay and/or skeletal defects.  

Short stature is one of the most common reasons for referral to a pediatric 	
endocrinologist. Next generation sequencing (NGS) has permitted the identification of 	
genetic defects in subgroups of short stature individuals, including heterozygous mutations in 	
the aggrecan gene (. 	
Aggrecan is a maj r structural component of the cartilage growth plate. Until recently, 	
mutations had been observed in a few families with spondyloepiphyseal dysplasia, 	
Kimberley type (SEDK, MIM 608361)1, spondyloepimetaphyseal dysplasia, aggrecan type 	
(SEMD, MIM 612813)2, and osteochondritis dissecans (MIM 165800).3 More recently, 	
through the implementation of NGS, heterozygous  mutations have been reported in 		
individuals with a milder skeletal dysplasia, presenting with short stature and advanced bone 	

age (BA).410 This led to the creation of an International Aggrecan Consortium for the clinical 

and genetic evaluation of 103 ACAN heterozygotes from 20 families.6 Height appeared to be 

less affected during childhood (median 2 SDS), and most had advanced BA compared to 

chronological age (CA).  

Aggrecan consists of an Nterminal domain, two globular domains (G1 and G2), two 

interglobular domains (CS and KS attachment regions), a selectinlike domain (G3) and a C

terminal domain.11Mutations are located throughout the protein and no genotypephenotype 

correlations have been observed.6,10 The pathogenic mechanisms for the accelerated bone 

maturation, cartilage degradation and the clinical heterogeneity remain elusive.  
	
We present a retrospective study of the clinical and genetic findings of 16 probands 


with heterozygous variants, detected during routine genetic studies using a skeletal 
dysplasia NGS panel. We also review all cases reported in the literature to determine the 
frequency of the different clinical characteristics related to agrecanopathies. 
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All participants provided informed consent for the performed studies and ethical 
approval was obtained from the Hospital La Paz ethical committee. 
The 16 probands were referred for molecular study from Spanish and Portuguese 
endocrinology and genetic clinics. Ten formed part of a cohort of 100 children with short 	
stature and mild skeletal defects in either the proband or one of their parents, in whom 	 

defects had been previously excluded using MLPA (P018G1, MRC Holland) and DNA 
sequencing. Endocrine disorders including GHIGF1 related conditions were also excluded 
by biochemical analysis. The remaining six probands were referred for routine skeletal 
dysplasia genetic diagnosis (n>1000 patients). 	 mutations were similarly excluded in 
four of these, not performed in probands 1516. BA and skeletal surveys were performed. 
Blood samples were extracted from the proband and family members, when available. 
All probands were analysed using a custom designed Skeletal dysplasia Next 
generation sequencing (NGS) panel, SKELETALSEQ.V36 (n=315368 genes) and 
sequenced on a MiSeq/NextSeq sequencer (Illumina, San Diego, CA, USA). Bioinformatic 	
analyses were performed as previously described.11  Conservation, pathogenicity prediction 

analysis and population frequences of the identified variants was carried out using 
CADD V1.3 (http://cadd.gs.washington.edu/), GerpRS 
(http://mendel.stanford.edu/SidowLab/downloads/gerp/) and Alamut V2.10 (Interactive 
Biosoftware, France) and gnomAD database (http://gnomad.broadinstitute.org). Variants 
were subsequently validated by Sanger sequencing as was family testing. Kinship was 
confirmed using microsatellite marker analysis (Devyser Complete QFPCR, Stockholm, 
Sweden).   
After the identification of an variant, each referring clinician was asked to 
complete a specific aggrecanopathy clinical questionnaire including personal and familial 	
records, anthropometric measures, facial dysmorphisms, age of puberty onset and pubertal 

spurt and other associated medical conditions, similar to that previously published.6 
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Advanced BA was defined as a BA greater than one year compared to the CA, whilst 
delayed BA was defined as BA less than one year relative to the CA. Brachydactyly was 
defined as short metacarpals and/or fingers. The clinical data, BA and skeletal surveys were 
then revised by three experts (LSM, AO, MP). Subsequently, the 16 probands were divided 
into two clinical groups: those presenting with short stature and mild skeletal defects (group 
1, probands 114) and two with SEDK (group 2, probands 1516).  
 
(*&	



A total of 16 heter zygous variants were identified (Figure 1, Table 1). No 
other pathogenic mutation or variant of unknown significance (VUS) associated with short 
stature and skeletal defects, including brachydactyly, was detected in the probands. Six 
variants were classified as pathogenic mutations (4 nonsense, 1 frameshift and 1 splicing) 
whilst the remaining ten were classified as VUS (Table 1) using the American Society of 
College of Genetics and Genomics (ACMG) recommendations for classifying variants.12 
Family testing was performed in all 16 probands. Mutations were inherited in all but 
one case (proband 9) which appears to have arisen as a  event or due to germinal 
mosaicism. The variants were identified in a total of 20 family members, 19 adults and one 	
child, all with short stature and/or mild skeletal defects or SEDK (fathers of probands 15 and 

16). Unfortunately, further cosegregation studies from multiple generations were not 
possible. 
 
 !"
Thirteen of the 14 probands were children (age range 1.518 years, median 10.2 
years). Probands 1 and 13 were previously included in the International Aggregation 
consortium study.6 Clinical characteristics are shown in Table 2. Anthropometric 
measurements were assessed in the 13 children of group 1. The median height SDS was 
below average (2.9), sitting heighttoheight ratio was in the normal range (0.54) and BMI 	
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
was 0.31 SDS. Advanced BA was observed in three probands whilst equal or delayed BA 

with respect to CA was determined in ten. Three probands had reached their final height, two 
of whom had had a poor pubertal spurt. Examples of growth patterns are shown in Supp. Fig. 
1. Radiological features and hand photos are shown in Supp. Fig. 2 and 3, respectively. 
Brachydactyly (short fingers and/or short metacarpals) was observed in all probands in group 
1. Seven probands (53%) showed a similar phenotype with frontal bossing, depressed nasal 
bridge and/or midfacial dysplasia (Table 2). Three of the patients (probands 2, 9, 12) have 
recently initiated growth hormone therapy, but no response data is currently available.  To 
determine if the clinical characteristics were similar or different in individuals with a clearly 
pathogenic mutation compared to those with a VUS, we performed a comparison of the 	
clinical and radiological characteristics of these probands from group 1 (Table 3).  

 
#$%&'()*+
Heterozygous  mutations were identified in the two probands with moderate 
skeletal anomalies including platyspondyly, whom were subsequently diagnosed as having 
SEDK (Table 1). Proband 15 was found to have a mutation in the canonical splice acceptor 
site of intron 1 (c.72A>C) which is predicted to result in the removal of exon 2, where the 
initiation codon is located. We demonstrated, using a minigene assay, that this mutation 
indeed ablated the intron 1 splice acceptor site, thus, confirming the pathogenicity of this 
variant (Supp. Fig. 4). The second case, proband 16, has a missense variant (VUS) in  	
(p.Thr533Ile). Clinical and radiological characteristics of both probands are shown in Table 4 

and Supp. Fig.2, respectively.  	
  	
$$%	
A total of 16 heterozygous variants were detected throughout , 14 in individuals 	
with short stature, mild skeletal defects and/or facial dysmorphisms (group 1) and two with 	
SEDK (group 2). No other mutation/variant was identified in the skeletal dysplasia patient in 	
the 16 probands which could explain their phenotype. As functional characterization is not 	
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
currently feasible for confirming the pathogenicity of the ACAN VUS variants, we compared 	
the clinical features in probands from group 1 with a pathogenic mutation (nonsense, 		
frameshift, splicing, n=5) and those with VUS (missense variants, n=8) (Table 3). Individuals 	

with a pathogenic mutation were shorter (median 3.33 v 2.7 SDS) and 60% had an 

advanced BA compared to 0% in those with a VUS. Advanced BA:CA was only observed in 

3/5 individuals with a pathogenic mutation, thus, two individuals had a BA equal or delayed 

with respect to the CA. To date, a total of 58 probands and 106 family members (total =164 

heterozygous  positive individuals with short stature and mild skeletal defects) have 

been reported in this study and in the literature (Table 5).410. Although advanced BA is a 

good indicator for the presence of mutations in , it cannot be the principal selection 

criteria. The other major difference was that a third of the individuals with a VUS had coxa 

valga whereas no individual with a pathogenic mutation presented with this clinical feature. 
	
Nevertheless, other features such as skeletal defects, facial dysmorphisms and precocious 


arthropathy or discopathy were present at similar frequencies in both variant classification 
groups. An interesting observation and in contrast to previous data, brachydactyly was 
observed in all probands. 
After analysing the individuals according to the variant classification, we performed a 
study of the clinical features of the probands and affected family members from group 1 
(n=32; 14 children and 18 adults). No sex or ethnic differences were observed. Only 23% of 
the children had advanced BA, once again significantly lower than that previously described 
(Table 5). The degree of short stature was also very variable. Another previously 
undescribed feature was the presence of mild hip abnormalities in five probands (38%). 	
Parents of two of these probands suffer with osteoarthritis. Osteoarthritis and disc disease 

were uncommon in our cohort with only three parents having these medical complications 
(23%) (Table 5).  
Clinical heterogeneity occurred in some families, as previously reported in a few 
cases.6,10 Proband 3 (p.Ala248Thr VUS) presents with normal stature although in the lower 
range (1.8 SDS), BA equal to CA but has brachydactyly and minor skeletal defects. He has 
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
not yet reached adult height and early growth cessation occurs in this growth disorder. His 
mother, with the same variant, presents with short stature (3 SDS), precocious osteoarthritis 
and discopathy. Thus, the differences in height and clinical presentation are likely to be 
associated with age. In a similar way proband 12 (p.Glu2426Lys VUS) presents with short 	
stature (2.5 SDS), BA equal to CA, mild dysmorphic features and skeletal defects. Her 

father has the same variant but has normal stature although within the lower limit (1.79 
SDS) and only brachydactyly. This clinical heterogeneity is similarly observed in other 
skeletal dysplasias such as those associated with heterozygous 	or,-$mutations.13 
Two heterozygous  variants (1 pathogenic, 1 VUS) were identified in two 
individuals with SEDK. To date, only one SEDK case with an ACAN mutation in the CS1 
domain, has been reported in the literature.1 Prior to the implementation of NGS patients with 
this form of spondyloepiphyseal dysplasia were generally tested for mutations in /$ 
and if negative, remained molecularly undiagnosed. Thus, further cases may be identified in 
the future. 	
Interestingly, proband 6 presented with Madelung deformity and proband 15 and his 

father, considered to have SEDK, have curved radii and limited elbow extension. Madelung 
deformity is typically observed in individuals with LériWeill dyschondrosteosis (MIM 127300), 
isolated or due to posttraumatic conditions.14 SHOX defects have been excluded in all 
probands. This observation is not that surprising since SHOX binds to SOX5 and SOX6 
which along with SOX9 (SOX trio) activate an aggrecan enhancer, thus, participating in 
common regulatory pathways in chondrogenesis.15 
The description of our cohort supports the undertaking of a detailed clinical 
examination and skeletal survey in short stature individuals with suspicion of a mild skeletal 
dysplasia. Our observation of an association with brachydactyly may help clinicians to 	
request genetic analysis of .  

For now, the diagnosis of this dysplasia is paramount for patients and their families. 
Individuals with  mutations are at risk of short stature, early growth cessation and poor 
pubertal spurt, and other health related problems such as obesity and orthopaedic problems 
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
should be prevented or their effects reduced. Careful monitoring of patients with 
mutations may help us to identify important genotypephenotype correlations and to 
understand their longterm clinical outcomes. Additional familial studies, analysis of larger 
cohorts, generation of animal models and functional analysis will be also required in order to 
determine the incidence of ACAN mutations and the pathogenic mechanism(s)16.  
	
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1 c.61G>T  
(p.Glu21*) 
2 G1A 5.3  35     2 Pathogenic  
 
2 c.371G>A  
(p.Arg124His) 
3 G1A 5.36 High 24.9 Del Possdam Dis Caus Fin:0.0046,       
Lat: 0.0029, 
NFE: 0.0017 
1 VUS 
3 c.742G>A 
 (p.Ala248Thr) 
5 G1B 5.36 High 24.9 Del Probdam Dis Caus Eur: 0.0063 
Lat: 0.0058 
SA: 0.0032 
Fin: 0.0011 
EA: 0.0053 
1 VUS  
4 c.903G>C  
(p.Trp301Cys) 
6 G1B´ 5.56 High 24.7 Del Probdam Dis Caus  2 VUS 
 
5 c.1608C>A  
(p.Tyr536*) 
9 G2B 4.41  38     1 Pathogenic  
 
6 c.1930G>A 
(p.Gly644Ser) 
10 G2B´ 5.11 High 25.2 Del Probdam Dis Caus EA: 0.074 
Afr: 0.0041 
SA: 0.0032 
NFE: 0.0008 
1 VUS  
7 c.1948G>A 
(p.Val650Met) 
10 G2B´ 5.11 High 25.4 Del Prob dam Dis Caus NFE: 0.027 
Lat: 0.026 
SA: 0.0065 
Afr: 0.0041 
1 VUS  
8 c.2218A>T  
(p.Thr740Ser) 
12 KS 5.77 High 22.1 Del Probdam Dis Caus NFE: 0.008 1 VUS  
9 c.2369C>G  12 KS 5.77  22.1     0 Pathogenic 
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
(p.Ser790*)   
10 c.6142C>G 
(p.Pro2048Ala) 
12 CS2 5.26 High 18. 5 Del Possdam Poly NFE: 0.022 
SA: 0.022 
Lat: 0.0029 
1 VUS 
11 c.7269delG 
(p.Glu2424fs*5) 
15 G3        
 
2 Pathogenic 
12 
c.7276G>A 
(p.Glu2426Lys) 
16 G3 5.69 High 35 Del Probdam Dis Caus 
EA: 0.084     
 SA: 0.035        
Afr: 0.021 
NFE: 0.0031         
Lat: 0.0029        
1 VUS  
13 c.7276G>T  
(p.Gly2426*) 
16 G3 5.69 High 56  
   2 Pathogenic 
 
14 c.7342G>A 
(p.Gly2448Arg)
π
 
17 G3 5.31 High 23.5 Del Probdam Dis Caus NFE: 0.026 
Afr: 0.016 
Lat: 0.014 
SA: 0.0032 
2 VUS  
15 c72A>C* Intron 1         1 Pathogenic 
16 c.1598C>T  
p.(Thr533Ile) 
 
9 G2B 4.49 High 23.7 Del Probdam Dis Caus  1 VUS 
 
The coordinates are according to  transcript NM_013227.3. Aggrecan domains: G1 (A, B, B´) and G2 (B, B´) globular domains, 
chondroitin (CS) and keratin (KS) sulphate attachment regions, selectinlike domain (G3).  Del: Deleterious, Tol: Tolerated, Prob dam: 
Probably Damaging, Poss dam: Possibly Damaging, Dis Caus: Disease causing, Poly: Polymorphism. CADD V1.3 values >14 were 
classified as deleterious. Patients 1 and 13 were included in the International Aggrecan Consortium (Gkourogianniet al, 2017). The gnomAD 
MAF: T: Total; NFE: NonFinnish European; Lat: Latin; Afr: African; EA: East Asian; Fin: Finish; SA: South Asian. Highly conserved amino 
acid (AlamutV2.10).
π
Splicing tools in Alamut V2.10 predicted that it may affect splicing but a minigene assay did not confirm these 
Page 14 of 29Clinical Endocrinology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
For Peer Review
14 

predictions.*Splicing tools predict the ablation of intron 1 canonical splice acceptor site, which was subsequently confirmed using a minigene 
assay.
 

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1 Sp c.61G>T 
(p.Glu21*) 
4.5 F N 3.5 3.0 0.56 +1.5 + + +         + +    2 3 
1.5 
2 Sp c.371G>A 
(p.Arg124His) 
8.0 F N 3.7 2.4 0.54 2     + + +     + + +  
 
 1 2.7 
3 Ec c.742G>A 
(p.Ala248Thr) 
14.5 M N 1.8 2.6 0.52 =           NA +  + Mildly 
flattened 
capital 
femoral 
epiphyses, 
slender 
femora 
 
 
Osteoarthritis 
and 
discopathy in 
mother 
1 3 
4 Sp c.903G>C 
(p.Trp301Cys) 
7.0 F N 3.5 3.6 NA =  + + +        +  + Slender 
femora 
Osteochondr
al knee mild 
defects 
Familiar 
osteochondriti
sdissecans in 
affected 
father and 
uncle 
2 4.4 
3.8 
5 Sp c.1608C>A 
(p.Tyr536*) 
4.5 F N 3.5 3.0 0.6 +1            +   Osteochondr
al knee mild 
defects 
 
Osteoarthritis 
in father 
1 4.5 
 
6 Ch c.1930G>A 
(p.Gly644Ser) 
16.0 F N 2.1 2.0 0.57 =           NA +   Madelung 
deformity, 
short femoral 
necks, mild 
epiphyseal 
knee defects 
 1 3.7 
7 Sp c.1948G>A 
(p.Val650Met) 
12.0 M N 2.6 1.4 0.52 3    +  +   +   +     1 2.6 
8 Sp c.2218A>T 
(p.Thr740Ser) 
3.0 M N 3.2 NA 0.57 1  + +    +   +  +     1 3.7 
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 
Geographic origin: Sp: Spain, Ec: Ecuador, Ch: China. Gender: M: Male; F: Female. SGA: N: No; Y: Yes. SH/H: Sitting height/height.BA vs CA: 
BA: Bone age; CA: Chronological age; +: BA>CA. =: BA=CA (equal), : BA<CA. BA>1y CA: Advanced (Adv). BA +/ 1y CA: Equal, BA<1y: 
Delayed, Eq/Del: Equal or Delayed. NA: Not available. Facial dysmorphisms and skeletal findings: +: Present; : Absent  
9 Sp c.2369C>G 
(p.Ser790*) 
14.5 M Y 2.2 0.6 0.52 +2  +   +   +   NA + +      
10 Sp c.6142C>G 
(p.Pro2048Ala) 
12.5 F Y 2.2 2.1 NA +1           NA +     1 2.3 
11 Sp c.7269delG 
(p.Glu2424fs*5) 
1.5 M N 3 3.2 NA +2    +        +     2 5.8 
3.8 
12 
Sp c.7276G>A 
(p.Glu2426Lys) 
8.5 F Y 2.5 1.8 NA =  +  +        +   Coneshaped 
epiphysis 
 1 1.79 
13 
Sp c.7276G>T 
(p.Gly2426*) 
18.0 M Y 4.3 3.4 0.54 = +          Poor +   Short femoral 
neck 
 2 5.0 
3.7 
14 Sp c.7342G>A 
(p.Gly2448Arg) 
46 F NA 3.7 4.3 0.52 NA  + +        Poor 
(11y) 
+     2 4.3 
3.5 
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
 
AD: Autosomal dominant, SGA: Small for gestational age, SH/H: Sitting height/height, BA vs. CA: Bone age v Chronological age, 
Adv: Advanced BA (>1 year),Equal/Delayed: BA equal to CA or delayed (<1 year). 
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4 AD 
1 de 
novo 
2 3.33 2.64 0.55 
 
3 Adv 
(60%) 
2 
Equal/Dela
yed (40%) 
 
 
4 
80% 
5 
100% 
2 
40% 
0 
0% 
2 
40% 
1 
20% 
 
5.8/1.5 
 
6
/		2
/=D2
8 AD 2 2.7 2.27 0.544 
 
8 
Equal/Dela
yed  
(100%) 
 
5 
62% 
8 
100% 
1 
12% 
3 
37% 
4 
50% 
2 
25% 
4.4/1.79 
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Geographic origin: Pt: Portugal, Sp: Spain. BA vs CA: BA: Bone age; CA: Chronological age; +: BA>CA (Advanced), =: BA=CA 
(Equal), : BA<CA (delay); NA: Not available.
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15 Pt c.72A>C  
(intron 1) 
M 7.5  Y 4.20 3.6 0.53 2 No Stocky 
appearance, 
short neck, 
limited elbow 
extension 
Brachydactyly, 
curved radius, mild 
platyspondyly 
Father´s height 3.66 SDS 
Stocky appearance, obese,  
brachydactyly with shortened 
metacarpals, curved radius, 
limited extension of elbows 
platyspondyly, coxarthrosis,  
16 
 
Sp c.1598C>T  
(exon 8) 
p.(Thr533Ile) 
(G2 domain) 
 
M 10 N 0.76 0.54 NA = No Obesity, short 
trunk, waddling 
gait 
Bilateral irregular 
femoral epiphyses, 
mild thoracic 
platyspondyly 
Father´s height 0.38 SDS, limp. 
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Nilsson et al, 
2014 (ref 4) 
14 (5/9)* 
3 families 
2/4 4/1.2 
3.8/2.3 
 
3/5 NR NR 6/9 6/9 3/9 NR NR NR NR 5/5 1/3 0/3 
Quintos et al,  
2015 (ref 5) 
3 (1/2)** 
1 family 
0/1 2.7 
4.7/2.6 
1/1 NR NR 1/3 NR NR NR NR NR NR 2/2 0/1  0/1  
Manouk van 
der Steen et al, 
2016 (ref 7) 
10 
(4/6) 
3 families 
3/3 3.7/2.4 
5.4/3.7 
3/4 NR NR 9/10 NR 3/10 6/10 3/10 NR NR NR 3/3  0/3  
Gkourogianni 
et al, 2017 
(International 
Aggrecan 
Consortium) 
(ref 6) 
102 ¥ 
(32/70) 
20 
families 
 
NR 4.2/0.6 
5.9/0.9 
19/23 
probands 
2/32 
probands 
8/20 8/20 
 
5/20 3/20 NR NR NR NR 23/70  13/20  8/20 
Dateki et al,  
2017 (ref 8) 
4 (2/2) 
1 family 
0/2 2.7/2.5 
3.1/3 
2/2 NR NR 3/4 NR NR NR 1/4 NR NR NR 0/1 1/1  
Hu et al,  
2017 (ref 9) 
9(3/6) 
3 families 
1/1 4.3/2.9 
5.4/2.9 
0/3 NR NR NR NR NR NR NR NR NR NR 0/3  0/3  
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
Hauer et al, 
2017 (ref 10) 
11(6/5) 
6 families 
1/6 3.9/2     
3.8/1.8 
2/5 3/6 NR NR 3/6 2/6 2/6 NR 1/6 NR NR 1/6 NR 
Current study 32 
(14/18)*** 
14 
families 
4/13 4.3/
1.86 
5.4/
1.79 
3/13 5/13 4/13 3/13 12/13 11/13 NR 3/13 5/13 3/13 6/6 3/14  1/14  

F
 ,-1
/3B>,@32
13
+	
,,>1@ 015A>0@5-
035B>0@5B
<D>13 B>1B 1>,9 <<>9B ,B><D ,B>9D D>,- A><A 3>,9 9>,9 <A>A1 <@>13 ,@>9B
 
Ns: nonsense mutation, Fs: frameshift mutation, Spl: splice donor site variant, Mis: missense variant, NR: not reported.* Three families are 
included in the International Aggrecan Consortium (5 children, 9 adults)6; **The family reported in this study is included in the International 
Aggrecan Consortium (1 child, two adults)6; *** Two families (two children, two adults) are included in the International Aggrecan Consortium 6. 
Results shown here are related to the paediatric cohort. ¥ Gkourogianni et al. 2017, reported a large cohort of probands and relatives 
(International Aggrecan Consortium). Clinical and molecular characteristics are related to the 20 families, not to individuals as with the other 
studies. In addition, data was compiled from both adults and children. We have attempted to separate this data when possible.  § Combined data 
from this current study and previous studies. The numbers documented for type of mutation, early onset arthritis/OD and intervertebral disc 	
disease data are given as the number of families whilst the other characteristics are totals for the number of individuals (probands or adults). 

Once again, most of the data from the International Aggrecan Consortium (¥ ref 6) cannot be summarized as the data is presented for families 
rather than individuals. Patients included in three earlier studies (*, **, ***) have not been duplicated in this data.  
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:	*		
:	,
	+%	+	 	+		,-
5The G1 region encoded by exons 36, the IGD region by exon 7, the G2 region 
by exons 810, the GAG (KSCS1CS2) attachment region encoded by exons 1112 while 
the G3 region encoded by exons 1319. Missense variants written in black whilst premature 
truncating (nonsense, frameshift, splicing) mutations written in red. Mutations corresponding 
to SEDK written in blue. Families with osteoarthritis and/or discopathy underlined. 	
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